FDA Brief

Warning letters Drugs

FDA warning letter to

BioAsia Worldwide Sdn Bhd

High riskIssued Mar 25, 2025Posted May 13, 2025Center for Drug Evaluation and Research (CDER)

FDA warned BioAsia Worldwide over current good manufacturing practice violations for OTC drugs.

What happened

FDA inspected BioAsia Worldwide’s drug manufacturing facility in Sitiawan, Perak, Malaysia, from October 14 to 17, 2024. FDA found violations of current good manufacturing practice (CGMP) for finished pharmaceuticals, including missing component identity testing, inadequate finished-product release testing, weak stability studies, no process or cleaning validation, and poor quality-unit oversight. FDA placed products offered for import into the United States from the firm on Import Alert 66-40 on February 20, 2025.

What FDA found

  1. The firm did not test each component lot for identity and relied on supplier certificates of analysis without verifying supplier test reliability.

    21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)
  2. The firm did not perform appropriate laboratory testing of each finished drug batch for identity and strength before release, relying on appearance and odor.

    21 CFR 211.165(a)
  3. The firm did not run adequate stability studies to support storage conditions and expiration dates, including strength testing and full shelf-life studies.

    21 CFR 211.166(a)
  4. The firm did not validate manufacturing processes or qualify equipment and cleaning processes for non-dedicated equipment.

    21 CFR 211.100(a)
  5. The quality control unit did not ensure adequate training and product reviews.

    21 CFR 211.22; 21 CFR 211.25(a); 21 CFR 211.180(e)

What FDA wants

FDA asks the firm to respond in writing within 15 working days with corrective actions and prevention plans, and says a qualified consultant should audit operations and evaluate CAPAs before the firm seeks resolution. FDA may re-inspect and may withhold approvals until violations are addressed.

Who should pay attention

  • US importers and distributors of OTC drugs made by this firm
  • brands that use this contract manufacturer for finished OTC drugs
  • quality teams auditing supplier certificates of analysis and release testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk